(Q39882249)

English

Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (English)

1 reference

Europe PubMed Central

15 September 2017

World Health Organization

0 references

3

1 reference

Europe PubMed Central

15 September 2017

Frederick G Hayden

2

object named as

Frederick Hayden

1 reference

Europe PubMed Central

15 September 2017

author name string

Iain Stephenson

1

1 reference

Europe PubMed Central

15 September 2017

Wendy Howard

4

1 reference

Europe PubMed Central

15 September 2017

Yuri Pervikov

5

1 reference

Europe PubMed Central

15 September 2017

Laszlo Palkonyay

6

1 reference

Europe PubMed Central

15 September 2017

Marie-Paule Kieny

7

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

14 April 2010

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

28

1 reference

Europe PubMed Central

15 September 2017

23

1 reference

Europe PubMed Central

15 September 2017

3875-3882

1 reference

Europe PubMed Central

15 September 2017

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Mapping the antigenic and genetic evolution of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Comparative efficacy of inactivated and live attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza virus-specific cytotoxic T cells in man; induction and properties of the cytotoxic cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Cytotoxic T-cell immunity to influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

T cell responses are better correlates of vaccine protection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

The effect of universal influenza immunization on mortality and health care use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Using plant cells as influenza vaccine substrates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

An in-built proteinase inhibitor system for the protection of recombinant proteins recovered from transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.03.074

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39882249&oldid=2092027200"